<DOC>
	<DOC>NCT01211509</DOC>
	<brief_summary>Chronic rejection (or Bronchiolitis Obliterans syndrome-BOS) is a major cause of mortality and morbidity after lung transplantation. Because montelukast has been shown to be of some efficacy in a similar disease (Obliterative Bronchiolitis after bone marrow transplantation), the investigators would like to test if montelukast can indeed slow down the progression of chronic rejection after lung transplantation.</brief_summary>
	<brief_title>Montelukast in Bronchiolitis Obliterans Syndrome</brief_title>
	<detailed_description>- Prospective, interventional, randomized, double-blind, placebo-controlled trial. - Clinical setting (tertiary University Hospital). - Investigator-driven, no pharmaceutical sponsor. - Lung transplant recipients. - Add-on of study-drug (placebo or montelukast) to 'standard of care' - 1:1 inclusion ratio (placebo:montelukast). - Randomisation at diagnosis of chronic rejection after informed consent.</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Diagnosis of fBOS Signed informed consent Age at least 18 years old at moment of transplantation Able to take oral medication Retransplantation Previous organ transplantation Multi organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>montelukast</keyword>
	<keyword>cysteinyl leukotriene</keyword>
	<keyword>lung transplantation</keyword>
	<keyword>bronchiolitis obliterans syndrome</keyword>
</DOC>